Core Insights - The session features Recordati's CEO Rob Koremans, along with Scott Pescatore, Head of R&D, and Mike McClellan, CFO, indicating a focus on leadership insights and strategic direction for the company [1] Company Overview - Recordati is participating in the 4th JPMorgan Healthcare Conference, highlighting its engagement with investors and stakeholders in the healthcare sector [1]

Summary of Pacira BioSciences FY Conference Call (January 14, 2026) Company Overview - **Company**: Pacira BioSciences (NasdaqGS:PCRX) - **Mission**: Deliver innovative, non-opioid pain management therapies to transform lives [2][3] - **Sales**: Reported unaudited sales of $726 million for the previous year [2] - **Employees**: Over 800 engaged employees [2] - **Patients Served**: More than 18 million patients helped to date [2] Product Portfolio - **Key Products**: - **Exparel**: Flagship product for nerve block - **Zilretta**: Long-acting corticosteroid for osteoarthritis pain - **Iovera**: Medical device using cryoneurolysis for pain management [3] Strategic Developments - **5x30 Strategy**: Aims to help over 3 million patients by 2030, achieve double-digit top-line growth, expand profitability by five points, add five new programs to the pipeline, and establish five partnerships [6][7] - **Partnerships**: - **Johnson & Johnson MedTech**: Triples reach for Zilretta [9] - **LG Chem**: Gains commercial rights for Exparel in Asia-Pacific, with potential for Zilretta sales [10] - **Intellectual Property**: Strong IP estate with 21 patents, providing robust defense against future Paragraph IV filers [5][12] Financial Performance - **Stock Performance**: 40% increase in stock price from January to December [5] - **Profitability**: Expected margins of 80%-82% for the current year [7] - **Share Buyback**: $150 million worth of stock repurchased, reducing outstanding shares to 41 million [11] Pipeline and Data Catalysts - **Upcoming Data Catalysts**: - **PCRX201**: Local gene therapy with promising phase one results [8][22] - **Iovera Spasticity**: Interim readout expected in the first half of the year [21] - **Zilretta for OA of the Shoulder**: Registrational study readout anticipated [21] Market Access and Growth Strategy - **NOPAIN Legislation**: Aimed at reducing opioid prescriptions; 102 million lives covered by the end of the year [19] - **Market Access**: Over 90% of business contracted, with ongoing efforts to educate stakeholders [20][44] - **Volume Growth**: Notable growth in the second half of the year, with 9% and 7% volume growth in Q3 and Q4 respectively [36] Challenges and Future Outlook - **Behavior Change**: Ongoing efforts to drive behavior change among healthcare professionals regarding non-opioid pain management [31] - **Market Education**: Continued focus on educating physicians and patients about the benefits of non-opioid options [41][43] - **Long-term Potential**: Exploration of additional indications for PCRX201, including potential for repeat dosing and expansion to other joints [33][35] Conclusion - **Overall Sentiment**: The company is optimistic about its growth trajectory, driven by a strong product pipeline, strategic partnerships, and a commitment to transforming pain management [28][30]

JP Morgan 44th Annual Healthcare Conference Frank D. Lee Chief Executive Officer PCRX | January 14, 2026 Forward-looking statements and where to find additional information Any statements in this presentation about Pacira's future expectations, plans, trends, outlook, projections and prospects, and other statements containing the words "anticipate," "believe," "can," "could," "estimate," "expect," "intend," "may," "plan," "project," "should," "will," "would," and similar expressions, constitute forward-look ...

Core Insights - Pacira BioSciences (PCRX) has entered a partnership with LG Chem to enhance access to opioid-sparing postsurgical pain management in select Asia-Pacific markets, granting LG Chem exclusive rights to commercialize Exparel [1][6] Group 1: Partnership Details - The agreement includes an undisclosed upfront payment, a transfer price, and tiered royalties on future sales generated by LG Chem in the licensed markets [2] - Pacira will manufacture Exparel, while LG Chem will manage regulatory filings and approvals, with plans to submit marketing authorization applications in South Korea and Thailand within six months [2][6] Group 2: Strategic Rationale - The partnership aims to extend Exparel's reach into Asia-Pacific markets, supporting Pacira's long-term growth strategy by tapping into a large surgical patient base [3] - Exparel's extended duration of action addresses the demand for advanced postsurgical pain management solutions in Asian markets, where reliance on short-acting analgesics is prevalent [4] Group 3: Financial Implications - The collaboration is expected to expand Exparel's commercial footprint and create new revenue channels outside the United States, which is crucial as Pacira reported preliminary fourth-quarter revenues of $196.9 million, a 5% year-over-year increase but below market expectations [9] - Management is positioning the international expansion of Exparel as a key lever to drive incremental sales and improve overall revenue momentum [9] Group 4: Product Portfolio - In addition to Exparel, Pacira's marketed portfolio includes Zilretta, an extended-release therapy for osteoarthritis knee pain, and the iovera system, a device for delivering cold temperature to targeted nerves [10]

Core Insights - Pacira BioSciences has partnered with LG Chem to expand access to opioid-sparing postsurgical pain control in select Asia-Pacific markets through the exclusive commercialization of EXPAREL [1][2] Company Overview - Pacira BioSciences is focused on delivering innovative, non-opioid pain therapies, with three commercial-stage products: EXPAREL, ZILRETTA, and iovera® [3] - EXPAREL is a long-acting local analgesic approved for various postsurgical pain management techniques [3] - ZILRETTA is an extended-release injectable for osteoarthritis knee pain management [3] - Iovera® is a handheld device providing immediate, long-acting, drug-free pain control [3] - The company is advancing a pipeline of clinical-stage assets, including PCRX-201, a gene therapy for osteoarthritis of the knee in Phase 2 development [3] Partnership Details - LG Chem will have exclusive rights to commercialize EXPAREL in the designated territories, leveraging its experience in orthopedic pain management [2] - Pacira will receive an undisclosed upfront payment, a transfer price, and tiered royalties on future sales by LG Chem [2] - LG Chem is responsible for obtaining regulatory approvals in the licensed territories, with plans to file for marketing authorizations in South Korea and Thailand within six months [2]

Core Insights - Pacira BioSciences (PCRX) reported preliminary, unaudited total revenues of $196.9 million for Q4 2025, missing the Zacks Consensus Estimate of $199 million, leading to a 9.6% decline in stock price [1][5] Group 1: Product Revenues - Exparel's net product sales reached $155.8 million in Q4 2025, a 5% increase from the previous year, slightly exceeding the Zacks Consensus Estimate of $155 million [3][5] - Zilretta's net product sales were reported at $33 million, remaining flat year over year and missing the Zacks Consensus Estimate of $34.4 million [6][7] - Iovera's net product sales amounted to $7 million, an 8% increase from the year-ago quarter, but fell short of the Zacks Consensus Estimate of $7.3 million [8] Group 2: Annual Performance - For the full year 2025, Pacira BioSciences reported total revenues of $726.4 million, a 4% increase year over year, but below the Zacks Consensus Estimate of $728.8 million [9]

Financial Performance - Preliminary unaudited total revenue for 2025 was $726.4 million, up from $701.0 million in 2024, representing a year-over-year increase of approximately 3.5%[1] - Full-year EXPAREL net product sales reached $575.1 million in 2025, compared to $549.0 million in 2024, reflecting a volume growth of 6%[4] - Fourth quarter EXPAREL net product sales were $155.8 million, an increase from $147.7 million in the same quarter of 2024, marking a volume growth of 7%[5] - Full-year ZILRETTA net product sales were $116.6 million in 2025, down from $118.1 million in 2024[12] - Full-year iovera° net product sales increased to $24.2 million in 2025, compared to $22.8 million in 2024[12] Share Repurchase and Cost Management - The company repurchased 2.0 million shares of common stock for $50.0 million during the fourth quarter, with $150.0 million remaining on its share repurchase authorization[7] - The company anticipates a reduction in force by July 2025, which is expected to yield cost savings[30] Strategic Initiatives - Pacira's strategic priorities, termed '5x30', focus on sustainable long-term growth and operational progress[2] - The company is focused on the commercialization of EXPAREL, ZILRETTA, and iovera°, with plans to expand their use to additional indications[32] - The success of EXPAREL, ZILRETTA, and iovera° is contingent on the timing and success of FDA supplemental New Drug Applications and EMA Marketing Authorization Applications[32] - The company is evaluating and developing additional product candidates utilizing proprietary multivesicular liposome (pMVL) drug delivery technology[32] Pipeline Development - The company is advancing its pipeline with PCRX-201, a gene therapy for knee osteoarthritis, currently in Phase 2 clinical development[26] - The company has identified numerous cytokines for potential locally administered genetic therapies using its high-capacity adenovirus vector platform[29] Gene Therapy Technology - The HCAd vector is significantly more efficient at delivering genes into cells compared to AAV vectors, allowing for effective treatment with smaller doses[31] - The HCAd platform can carry up to 30,000 base pairs of DNA, enabling gene therapy for multiple or larger genes[31] - Genetic medicines based on the HCAd platform can be administered locally and allow for potential redosing at therapeutically appropriate intervals[31] - The efficient delivery of genes means that thousands of doses can be produced in a single batch, leading to a commercially attractive cost of goods profile[31] Future Outlook and Risks - Pacira expects to report complete financial results for the fourth quarter and full-year 2025 in the first quarter of 2026[6] - Future growth potential and financial results are subject to various risks, including integration challenges from the acquisition of GQ Bio Therapeutics GmbH[30] - Actual results may differ materially from forward-looking statements due to known and unknown risks and uncertainties[33]

Core Insights - Pacira BioSciences reported record-high total revenue of $726.4 million for the year ended December 31, 2025, representing an increase from $701.0 million in 2024, driven by strong sales of EXPAREL and share repurchase activities [1][4][6] Revenue Highlights - Fourth quarter EXPAREL net product sales reached $155.8 million in 2025, up from $147.7 million in 2024, with a volume growth of 7 percent [8] - Full-year EXPAREL net product sales were $575.1 million in 2025, compared to $549.0 million in 2024, reflecting a 6 percent volume growth [8] - Fourth quarter ZILRETTA net product sales were $33.0 million in 2025, slightly down from $33.1 million in 2024 [8] - Fourth quarter iovera° net product sales increased to $7.0 million in 2025 from $6.5 million in 2024 [8] - Other revenue, including sales of bupivacaine liposome injectable suspension, was $1.1 million in the fourth quarter of 2025, compared to zero in the same period of 2024 [8] Share Repurchase Program - During the fourth quarter of 2025, the company repurchased 2.0 million shares of its common stock for $50.0 million, with $150.0 million remaining on its current share repurchase authorization [6] Strategic Outlook - The CEO emphasized the company's solid execution and progress in advancing its strategic priorities, positioning it for sustainable long-term success and significant revenue growth moving forward [2]

Core Insights - Pacira BioSciences, Inc. is committed to delivering innovative, non-opioid pain therapies to transform patients' lives [1][2] - The company will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 11:15 AM PST [1] Company Overview - Pacira has three commercial-stage non-opioid treatments: - EXPAREL, a long-acting local analgesic approved for various postsurgical pain management techniques [2] - ZILRETTA, an extended-release injectable for osteoarthritis knee pain management [2] - iovera®, a handheld device providing immediate, long-acting, drug-free pain control [2] - The company is advancing a pipeline of clinical-stage assets, including PCRX-201, a novel gene therapy in Phase 2 development for knee osteoarthritis [2]

Core Insights - Pacira Biosciences has joined the PROBE Consortium to enhance osteoarthritis research and patient care globally, leveraging data from over 70 million individuals [1][3] - The initiative aims to address significant unmet needs in osteoarthritis treatment, particularly due to a lack of innovation since the introduction of ZILRETTA [2][3] Company Overview - Pacira specializes in innovative, non-opioid pain therapies, with three commercial-stage products: EXPAREL, ZILRETTA, and iovera [4] - ZILRETTA is the first and only extended-release intra-articular therapy approved for osteoarthritis knee pain, providing pain relief for up to 16 weeks [5] PROBE Consortium Objectives - The PROBE initiative includes 38 partners from various sectors, aiming to transform osteoarthritis diagnosis and treatment through improved data analysis and trial designs [3][7] - Key strategies include creating a regulation-compliant database network, utilizing AI for disease progression predictions, and developing novel trial endpoints [7]